At meeting held on 10 September 2019
The Board of Directors of Sanofi India at its meeting held on 10 September 2019 approved a transaction for the slump sale and transfer of the manufacturing facility of the Company at Ankleshwar, Gujarat to Zentiva for a consideration of Rs. 261.7 crore, subject to customary working capital adjustments. This transaction is subject to approval of the members, which will be initiated by the Company through a postal ballot process and few other conditions as defined under the Business Transfer Agreement.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
